Mizolastine is effective and well tolerated in long-term treatment of perennial allergic rhinoconjunctivitis

Journal of International Medical Research

Volumn 27, Issue 6, 1999, Pages 273-285

  Scadding, G ^a   Tasman, A ^b   Murrieta Aguttes, M ^c   Bachert, C ^d  

^a ROYAL NATIONAL THROAT NOSE AND EAR HOSPITAL   (United Kingdom)

^b UNIVERSITY HOSPITAL HEIDELBERG   (Germany)

^c SANOFI   (France)

^d GHENT UNIVERSITY HOSPITAL   (Belgium)

Author keywords

Histamine H1 antagonists; Long term treatment; Mizolastine; Nasal blockade; Perennial allergic rhinitis

Indexed keywords

LIVER ENZYME; MIZOLASTINE; PLACEBO;

ADULT; ALLERGIC RHINITIS; ARTICLE; ASTHMA; BREAST AUGMENTATION; CELL COUNT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DROWSINESS; DRUG EFFICACY; DRUG SAFETY; FEMALE; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; NEUTROPHIL; NOSE AIRWAY RESISTANCE; PERENNIAL RHINITIS; RHINOCONJUNCTIVITIS; SCORING SYSTEM; SIDE EFFECT; VISUAL DISORDER;

EID: 0033490559     PISSN: 03000605     EISSN: None     Source Type: Journal    
DOI: 10.1177/030006059902700603     Document Type: Article

References (36)

1. Lundback B: Epidemiology of rhinitis and asthma. Clin Exp Allergy 1998; 28 (Suppl 3): S3-S10.
2. Bousquet J, Bullinger M, Fayol C, et al: Assessment of quality of life in patients with perennial allergic rhinitis with the French version of the SF-36 Health Status Questionnaire. J Allergy Clin Immunol 1994; 94: 182-188.
3. Juniper EF, Guyatt GH, Dolovich J: Assessment of quality of life in adolescents with allergic rhinoconjunctivitis: development and testing of a questionnaire for clinical trials. J Allergy Clin Immunol 1994; 93: 413-423.
4. Dykewicz MS, Fineman S, Skoner DP, et al: Diagnosis and management of rhinitis: complete guidelines of the Joint Task force on Practice Parameters in Allergy, Asthma and Immunology. American Academy of Allergy, Asthma, and Immunology. Ann Allergy Asthma Immunol 1998; 81: 478-518.
5. Bousquet J, Vignola AM, Campbell AM, et al: Pathophysiology of allergic rhinitis. Int Arch Allergy Immunol 1996; 110: 207-218.
6. Naclerio RM: Pathophysiology of perennial allergic rhinitis. Allergy 1997; 52 (Suppl 36): S7-S13.
7. Naclerio R, Soloman W: Rhinitis and inhalant allergens. JAMA 1997; 227: 1842-1848.
8. Rowe-Jones JM: The link between the nose and lung, perennial rhinitis and asthma - is it the same disease? Allergy 1997; 52 (Suppl 36): S20-S28.
9. Mackay IS, Durham SR: ABC of allergies. Perennial rhinitis. BMJ 1998; 316: 917-920.
10. International Rhinitis Management Working Group. Treatment of allergic rhinitis. Allergy 1994; 49 (Suppl 19): S19-S23.
11. Van Cauwenberge P, Wang D: Antihistamines and nasal blockade. Allergy 1997; 52 (Suppl 40): 35-38.
12. 1-antihistamine. Ann Allergy 1992; 69: 135-139.
13. Prakash A, Lamb HM: Mizolastine - a review of its use in allergic rhinitis and chronic idiopathic urticaria. Biodrugs 1999; 10: 41-63.
14. Pinquier J-L, Caplain H, Cabanis MJ, et al: Inhibition of histamine-induced skin wheal and flare after 5 days of mizolastine. J Clin Pharmacol 1996; 36: 72-78.
15. Rosenzweig P, Caplain H, Chaufour S, et al: Comparative wheal and flare study of mizolastine vs terfenadine, cetirizine, loratadine and placebo in healthy volunteers. Br J Clin Pharmacol 1995; 40: 459-465.
16. Pichat P, Angel I, Arbilla S: Anti-inflammatory properties of mizolastine after oral administration of arachidonic acid-induced cutaneous reactions in the rat. Arzneimittelforschung 1998; 48: 173-178.
17. Sudo K, Nagai K, Yamada N: Inhibitory effect of mizolastine on 5-lipoxygenase. Jpn Pharmacol Ther 1998; 26: 155-157.
18. Vargaftig BB: Mechanisms of bronchopulmonary hyperresponsiveness as related to eosinophils. In: New Developments in the Therapy of Allergic Disorders and Asthma, vol 6 (Langer SZ, Church MK, Vargaftig BB, et al, eds). Basel: Karger, 1993; pp27-32.
19. Goldhill J, Pichat P, Roome N, et al: Effect of mizolastine on visceral sensory afferent sensitivity and inflammation during experimental colitis. Arzneimittelforschung 1998; 48: G179-G184.
20. Michel L, Murrieta-Aguttes M, Jean-Louis F, et al: Inhibitory effect of oral mizolastine on in vivo antigen-induced soluble ICAM-1 release in human skin (skin chamber technique). Allergy 1996; 51 (Suppl 31): S373.
21. Stern MA, Darnell R, Tudor D: Can an antihistamine delay appearance of hay fever symptoms when given prior to the hay fever season? Allergy 1997; 52: 440-444.
22. Leynadier F, Bousquet J, Murrieta M, et al: Efficacy and safety of mizolastine in seasonal allergic rhinitis. The Rhinase Study Group. Ann Allergy Asthma Immunol 1996; 76: 163-168.
23. Stern M, Blondin-Ertzbischoff P, Murrieta-Aguttes M, et al: Rapid and sustained efficacy of mizolastine 10 mg once daily in seasonal allergic rhinitis. J Int Med Res 1998; 26: 292-303.
24. Bellioni P, Catalano B, Cervellera G, et al: Comparison of inizolastine with loratadine in the treatment of perennial allergic rhinitis. Rhinology 1996; 34: 101-104.
25. Bachert C, Brostoff J, Scadding GK, et al: Mizolastine therapy also has an effect on nasal blockade in perennial allergic rhinoconjuntivitis. RIPERAN Study Group. Allergy 1998; 53: 969-975.
26. Brostoff J, Fitzharris P, Dunmore C, et al: Efficacy of mizolastine, a new antihistamine compared with placebo in the treatment of idiopathic urticaria. Allergy 1996; 51: 320-325.
27. Dubertret L, Murrieta-Aguttes M, Tonet J, et al: Efficacy and safety of mizolastine 10 mg in a placebo-controlled comparison with loratadine in chronic idiopathic urticaria: results of the MILOR Study. J Eur Acad Dermatol Venereol 1999; 12: 16-24.
28. Patat A, Gram LF, Dubruc C, et al: Effect of mizolastine, a new antihistamine, on psychomotor performance and memory in elderly subjects. Int Clin Psychopharmacol 1994; 9: 101-108.
29. Vuurman EF, Uiterwijk MM, Rosenzweig P, et al: Effects of mizolastine and clemastine on actual driving and psychomotor performance in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 253-259.
30. Kerr JS, Dunmore C, Hindmarch I: The psychomotor and cognitive effects of a new antihistamine, mizolastine, compared to terfenadine, tripolidine and placebo in healthy volunteers. Eur J Clin Pharmacol 1994; 47: 331-335.
31. Ross RN: The costs of allergic rhinitis. Am J Managed Care 1996; 2: 285-290.
32. Carren J: Allergic rhinitis and asthma: how important is the link? J Allergy Clin Immunol 1997; 99: S781-S786.
33. Costa JJ, Weller PF, Galli SJ: The cells of the allergic response: mast cells, basophils and eosinophils. JAMA 1997; 278: 1815-1822.
34. Bousquet J, Chanal I, Murrieta M, et al: Lack of subsensitivity to mizolastine over 8-week treatment. Allergy 1996; 51: 251-256.
35. Wihl JA, Petersen BN, Petersen LN, et al: Effect of the nonsedative H1-receptor antagonist astemizole in perennial allergic and nonallergic rhinitis. J Allergy Clin Immunol 1985; 75: 720-727.
36. Lockey RF, Fox RW. Loratadine (SCH 29851) 10 mg o.d. versus clemastine 1 mg b.i.d. in the treatment of perennial allergic rhinitis. Immunol Allergy Pract 1989; XI: 423-429.